Novavax Receives the US FDA Emergency Use Authorization for NVX-CoV2373 in Adolescents Aged 12 Through 17 Years
Shots:
- The EUA decision was based on an ongoing pediatric expansion of the P-III (PREVENT-19) trial to evaluate two-dose primary series of COVID-19 vaccine in 2247 adolescents aged 12 through 17yrs. across 75 sites in the US
- The results showed that patients treated with the COVID-19 vaccine achieved its primary efficacy EPs with clinical efficacy of 78.29%. Analyses of antibody titers showed that they were higher in adolescents over young adults which corroborated the efficacy analyses
- The safety data showed that the vaccine was well-tolerated while local and systemic reactogenicity was lower than or similar to adults after the first and second dose with no new safety signal
Ref: PRNewswire | Image: Novavax
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
